drugset
Drugs / IDH1 peptide vaccine
last change Mar 2021 re-read 3 minutes ago

IDH1 peptide vaccine

also known as IDH1-vac

Vaccine targets IDH1

Developed for
glioma
Investigated by
German Cancer Research Center · National Center for Tumor Diseases, Heidelberg · Neuro-Oncology Working Group of the German Cancer Society · University Hospital Heidelberg

Trials 1

today NCT02454634 · Ph 1
201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02454634 Jun 2015 → Sep 2017 glioma National Center for Tumor Diseases, Heidelberg Completed Met primary

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as IDH1 peptide vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT02454634 ↗
Known as IDH1-vac “An IDH1(R132H)-specific peptide vaccine (IDH1-vac) induces specific therapeutic T helper cell responses that are effective against IDH1(R132H)+ tumours” PMID 33762734 ↗ Mar 2021
Modality Vaccine “An IDH1(R132H)-specific peptide vaccine (IDH1-vac)” PMID 33762734 ↗ Mar 2021
Route Subcutaneous “It is injected subcutaneously” NCT02454634 ↗
Target IDH1 “The NOA-16 trial is the first-in-man trial of the IDH1 (isocitrate dehydrogenase type 1) peptide vaccine targeting the IDH1R132H mutation” NCT02454634 ↗